tiprankstipranks
Trending News
More News >
Xeris Pharmaceuticals (XERS)
NASDAQ:XERS
US Market
Advertisement

Xeris Pharmaceuticals (XERS) Earnings Dates, Call Summary & Reports

Compare
1,038 Followers

Earnings Data

Report Date
Nov 06, 2025
Before Open (Confirmed)
Period Ending
2025 (Q3)
Consensus EPS Forecast
<0.01
Last Year’s EPS
-0.11
Same Quarter Last Year
Based on 5 Analysts Ratings

Earnings Call Summary

Q2 2025
Earnings Call Date:Aug 07, 2025|
% Change Since:
|
Earnings Call Sentiment|Positive
The earnings call reflected strong financial performance and growth, particularly in revenue and product demand. Key products like Recorlev showed exceptional growth, and the company successfully raised its revenue guidance. However, there were challenges with increased expenses affecting gross margin and SG&A costs.
Company Guidance
During the Xeris Biopharma Second Quarter 2025 Earnings Conference Call, the company announced a significant upward revision of its full-year 2025 revenue guidance to a range of $280 million to $290 million, reflecting a 40% year-over-year growth at the midpoint. Total revenue for the second quarter grew by 49% to $71.5 million, with net product revenue increasing by 46% to $67.7 million. Recorlev led the growth, with revenue surging 136% year-over-year to $31.4 million, driven by a 122% increase in the average number of patients on therapy. Gvoke also contributed with a 17% increase in revenue to $23.5 million, while Keveyis generated over $11 million in revenue. The company reported a gross margin of 82% and an adjusted EBITDA of $12.5 million, demonstrating strong operational efficiency. The positive outlook is supported by increased patient demand across all products and strategic investments in key growth drivers like Recorlev and the pipeline asset XP-8121.
Record-Breaking Revenue and Growth
Total revenue grew 49% year-over-year to a quarterly record of $71.5 million. The company raised its full-year revenue guidance to $280 million to $290 million, representing a 40% year-over-year growth at the midpoint.
Exceptional Growth of Recorlev
Recorlev revenue grew 136% year-over-year to $31.4 million, with the average number of patients on therapy increasing by 122%. This performance reinforces Recorlev's position as a key treatment option for Cushing's syndrome.
Positive Adjusted EBITDA
The company reported a positive adjusted EBITDA of $12.5 million, reflecting an improvement of nearly $13 million compared to the previous year.
Successful Analyst and Investor Day
The company's first-ever Analyst and Investor Day outlined the long-term vision and key growth drivers, notably Recorlev and the pipeline asset XP-8121, receiving positive engagement from the investment community.
Gvoke and Keveyis Steady Growth
Gvoke posted a 17% increase in revenue to $23 million, while Keveyis demonstrated its importance with revenue over $11 million, marking a modest increase.

Xeris Pharmaceuticals (XERS) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

XERS Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Nov 06, 2025
2025 (Q3)
<0.01 / -
-0.11
Aug 07, 2025
2025 (Q2)
-0.03 / -0.01
-0.190.00% (+0.09)
May 08, 2025
2025 (Q1)
-0.05 / -0.06
-0.1457.14% (+0.08)
Mar 06, 2025
2024 (Q4)
-0.06 / -0.03
-0.170.00% (+0.07)
Nov 08, 2024
2024 (Q3)
-0.09 / -0.11
-0.09-22.22% (-0.02)
Aug 08, 2024
2024 (Q2)
-0.10 / -0.10
-0.1428.57% (+0.04)
May 09, 2024
2024 (Q1)
-0.11 / -0.14
-0.12-16.67% (-0.02)
Mar 06, 2024
2023 (Q4)
-0.09 / -0.10
-0.10.00% (0.00)
Nov 09, 2023
2023 (Q3)
-0.10 / -0.09
-0.1643.75% (+0.07)
Aug 08, 2023
2023 (Q2)
-0.12 / -0.14
-0.1926.32% (+0.05)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

XERS Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Aug 07, 2025
$5.49$6.60+20.22%
May 08, 2025
$4.48$5.16+15.18%
Mar 06, 2025
$3.77$4.13+9.55%
Nov 08, 2024
$3.36$3.47+3.27%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Xeris Pharmaceuticals (XERS) report earnings?
Xeris Pharmaceuticals (XERS) is schdueled to report earning on Nov 06, 2025, Before Open (Confirmed).
    What is Xeris Pharmaceuticals (XERS) earnings time?
    Xeris Pharmaceuticals (XERS) earnings time is at Nov 06, 2025, Before Open (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is XERS EPS forecast?
          XERS EPS forecast for the fiscal quarter 2025 (Q3) is <0.01.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis